Eye health company Bausch + Lomb Corporation (NYSE:BLCO) (TSX:BLCO) announced on Monday that an affiliate has acquired Whitecap Biosciences, a company developing innovative therapies for glaucoma and geographic atrophy (GA).
This acquisition strengthens Bausch + Lomb's clinical-stage pipeline.
Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases. The company successfully completed Phase 2 clinical trials for WB007, a highly potent alpha-2 adrenergic agonist, in glaucoma. Further clinical trials are planned for both glaucoma and GA.
Glaucoma is a chronic neurodegenerative disease that affects millions of people worldwide. GA, a form of age-related macular degeneration, affects approximately one million people in the United States.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA